tiprankstipranks
Trending News
More News >

Peijia Medical Achieves Milestone with Trilogy Heart Valve Implants in Taiwan

Story Highlights
  • Peijia Medical successfully completed two implants with its Trilogy Heart Valve System.
  • This advancement could strengthen Peijia’s market position in treating severe aortic conditions.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

The latest announcement is out from Peijia Medical Ltd. ( (HK:9996) ).

Peijia Medical Ltd. has announced the successful completion of the first two implants using its Trilogy Transcatheter Heart Valve System in Taiwan, China. This development marks a significant milestone in the company’s product deployment and could enhance its position in the medical device market, particularly in addressing severe aortic regurgitation and stenosis in high-risk patients.

More about Peijia Medical Ltd.

Peijia Medical Ltd. is a company incorporated in the Cayman Islands, operating in the medical device industry. It focuses on developing and marketing transcatheter heart valve systems, particularly for treating severe aortic conditions.

YTD Price Performance: -6.25%

Average Trading Volume: 524

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €310M

Find detailed analytics on 9996 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App